Opus Point Partners Management as of June 30, 2018
Portfolio Holdings for Opus Point Partners Management
Opus Point Partners Management holds 50 positions in its portfolio as reported in the June 2018 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| SPDR S&P Biotech (XBI) | 12.0 | $5.5M | 58k | 95.19 | |
| Proshares Tr pshs ult nasb (BIB) | 11.6 | $5.4M | 94k | 57.20 | |
| Mettler-Toledo International (MTD) | 4.5 | $2.1M | 3.6k | 578.74 | |
| iShares NASDAQ Biotechnology Index (IBB) | 4.5 | $2.1M | 19k | 109.81 | |
| Alexion Pharmaceuticals | 3.7 | $1.7M | 14k | 124.14 | |
| Vertex Pharmaceuticals Incorporated (VRTX) | 3.4 | $1.6M | 9.3k | 169.97 | |
| Mei Pharma | 3.4 | $1.6M | 400k | 3.94 | |
| Illumina (ILMN) | 3.2 | $1.5M | 5.4k | 279.33 | |
| Alnylam Pharmaceuticals (ALNY) | 3.0 | $1.4M | 14k | 98.50 | |
| Seattle Genetics | 3.0 | $1.4M | 21k | 66.38 | |
| Agios Pharmaceuticals (AGIO) | 2.9 | $1.3M | 16k | 84.25 | |
| Loxo Oncology | 2.6 | $1.2M | 6.9k | 173.48 | |
| Qiagen Nv | 2.6 | $1.2M | 33k | 36.16 | |
| Fibrogen (FGEN) | 2.5 | $1.2M | 18k | 62.58 | |
| Proqr Thrapeutics N V shs euro (PRQR) | 2.4 | $1.1M | 154k | 7.30 | |
| Amgen (AMGN) | 2.4 | $1.1M | 5.9k | 184.65 | |
| Alkermes (ALKS) | 2.3 | $1.1M | 26k | 41.17 | |
| Biogen Idec (BIIB) | 2.2 | $1.0M | 3.5k | 290.20 | |
| Ionis Pharmaceuticals (IONS) | 2.2 | $997k | 24k | 41.69 | |
| BioMarin Pharmaceutical (BMRN) | 2.1 | $974k | 10k | 94.23 | |
| Regeneron Pharmaceuticals (REGN) | 2.0 | $931k | 2.7k | 345.07 | |
| Incyte Corporation (INCY) | 1.8 | $826k | 12k | 67.04 | |
| Celgene Corporation | 1.7 | $772k | 9.7k | 79.39 | |
| Clovis Oncology | 1.3 | $591k | 13k | 45.46 | |
| Tesaro | 1.1 | $511k | 12k | 44.43 | |
| Akebia Therapeutics (AKBA) | 1.1 | $499k | 50k | 9.98 | |
| Ultragenyx Pharmaceutical (RARE) | 1.1 | $485k | 6.3k | 76.85 | |
| Axsome Therapeutics (AXSM) | 0.9 | $427k | 134k | 3.20 | |
| Nektar Therapeutics (NKTR) | 0.9 | $417k | 8.5k | 48.87 | |
| Pacira Pharmaceuticals (PCRX) | 0.9 | $401k | 13k | 32.08 | |
| Adamas Pharmaceuticals | 0.8 | $387k | 15k | 25.80 | |
| Intercept Pharmaceuticals In | 0.7 | $335k | 4.0k | 83.79 | |
| Checkpoint Therapeutics | 0.7 | $336k | 113k | 2.98 | |
| Charles River Laboratories (CRL) | 0.7 | $307k | 2.7k | 112.29 | |
| Gilead Sciences (GILD) | 0.7 | $301k | 4.3k | 70.81 | |
| Neurocrine Biosciences (NBIX) | 0.7 | $301k | 3.1k | 98.21 | |
| United Therapeutics Corporation (UTHR) | 0.7 | $301k | 2.7k | 113.16 | |
| Exelixis (EXEL) | 0.6 | $292k | 14k | 21.54 | |
| Bio-techne Corporation (TECH) | 0.6 | $282k | 1.9k | 147.88 | |
| Iqvia Holdings (IQV) | 0.6 | $278k | 2.8k | 99.68 | |
| Grifols S A Sponsored Adr R (GRFS) | 0.6 | $268k | 12k | 21.54 | |
| Medicines Company | 0.6 | $257k | 7.0k | 36.71 | |
| Bluebird Bio (BLUE) | 0.6 | $256k | 1.6k | 156.96 | |
| Intrexon | 0.5 | $245k | 18k | 13.94 | |
| ACADIA Pharmaceuticals (ACAD) | 0.5 | $234k | 15k | 15.27 | |
| Paratek Pharmaceuticals | 0.4 | $204k | 20k | 10.20 | |
| Contrafect | 0.4 | $166k | 75k | 2.21 | |
| Progenics Pharmaceuticals | 0.2 | $88k | 11k | 8.08 | |
| Recro Pharma (SCTL) | 0.1 | $63k | 13k | 4.99 | |
| Scynexis | 0.1 | $55k | 33k | 1.65 |
